---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-006506"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-27T00:13:41.246961+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell reports Q4 net loss $0.17/sh; cash $55.7M; Roche deal up to $670M

## Summary
- Q4 2021 net loss $29.0M ($0.17/sh) vs net income $2.0M ($0.01/sh) in Q4 2020; FY 2021 net loss $43.0M ($0.26/sh).
- Cash and equivalents $55.7M at Dec 31, 2021; received $50M upfront from Roche/Genentech OpRegen collaboration in Jan 2022.
- Roche/Genentech deal for OpRegen (RG6501) worth up to $670M plus double-digit royalties; four dry AMD patients showed retinal restoration.
- R&D expenses $24.8M in Q4, driven by $21.0M accrual for future obligations to Israel Innovation Authority and Hadasit.
- 2022 milestones include new pipeline program announcement, OPC1 manufacturing improvements, and VAC2 IND submission in 2H 2022.

## SEC filing metadata
- accession: 0001493152-22-006506
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000149315222006506/0001493152-22-006506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000149315222006506/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-006506
- JSON: https://secwatch.observer/filing/0001493152-22-006506.json
- Plain text: https://secwatch.observer/filing/0001493152-22-006506.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.